Restoring Function in TBI with Stem Cell Therapy: Bijan Nejadnik, MD
The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.
Expanding the Understanding of ALS With New Methods: Brian Wainger, MD, PhD
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.
FDA Approves TBI Blood Test, Causal Link Between Smoking and Subarachnoid Hemorrhage, Inconsistencies Across EEG Education
Neurology News Network for the week ending January 23, 2021.
Future Studies on Cenobamate for Epilepsy: William Rosenfeld, MD
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, also discussed future studies planned for cenobamate.
S1P Receptor Modulators for Treatment of RMS
Stem Cell Therapy for TBI: Masahito Kawabori, MD, PhD
The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.
Analytical Approach to Changing EEG Education: Fabio Nascimento, MD
The clinical fellow at Massachusetts General Hospital provided background on his efforts to raise awareness of inconsistencies with EEG education in neurology residency programs.
Focal Seizures: Post-hoc Analysis of Cenobamate
Challenges of Treating Chronic Insomnia: Jennifer Martin, PhD
The AASM board of directors member and professor of medicine at UCLA also discussed the relative inefficacy of sleep hygiene therapy for insomnia.
Cladribine for Treatment of RMS
ELEKTRA Study in Dravet and Lennox-Gastaut Syndromes
Pavel Klein, MD: Determining Likelihood of Efficacy and AEs in Patient Populations
The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.
Richard B. Lipton, MD: Achieving Simultaneous Acute and Preventive Migraine Treatment
The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.
Anti-CD20 Monoclonal Antibodies for Treatment of RMS
The Role of Developing Agents in Acute Migraine Paradigm
CGRP Receptor Agonists: Safety and Efficacy
5-HT1F Agonist Toxicity Profile and Role in Paradigm
The Significance of 5-HT1F Agonist Approval
Recent Approvals for Acute Migraine
The Importance of Patient Communication
Therapy Assessment: Pain Relief & Onset Monitorization
Acute Migraine Treatment: Pain Freedom and Guidelines
Goals of and Recommended Approach for Acute Treatment
Acute Migraine Management: Overview and Unmet Needs
Safety and Efficacy of CBD in Patients With TSC
William Rosenfeld, MD: Reducing Concomitant ASM Dosages for Focal Seizures
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
Raymond Sanchez, MD: Phase 2 Trial Data of Tavapadon in Parkinson Disease
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
Donanemab Shows Decline in Alzheimer, Pfizer DMD Study Launched, REM Not Correlated With Seizures
Neurology News Network for the week ending January 16, 2021.
Strategies for Choosing Initial Therapy in MS
Clinical Benefit of Fenfluramine in Dravet Syndrome
